Published on

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  2. 2. RANBAXY Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. For more than 50 years, it has been providing high quality, affordable medicines trusted by healthcare professionals and patients across geographies. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan. It has ground operations in 43 countries and 16 manufacturing facilities spread across 8 countries. It has also covered all the top 25 pharmaceutical markets of the world and has a robust presence across both developed and emerging markets.
  3. 3. Offering High Quality, Affordable Pharmaceuticals: Ranbaxy is a vertically integrated company that develops, manufactures and markets Generic, Branded Generic, Value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. It has a large portfolio of over 500 molecules that cover multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Their presence extends across therapies and includes Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and Urology. Biotech and Vaccines are two new segments that we have begun investing in. A stronger presence in these areas will add significant depth to the existing product pipeline. Through their unique hybrid business model involving Daiichi Sankyo, they also introduce innovator products in markets around the world. Driven by Innovation: Their continued focus on Research & Development (R&D) has resulted in several regulatory approvals in both developed and emerging markets. They have multiple R&D centres in Gurgaon, Haryana, India with facilities for generic and innovative research. Their scientists have given India its first New Chemical Entity (NCE) that was launched on April 25, 2012. The product, SynriamTM, is a new age cure for Malaria. With a strong focus on research in generics, they are increasingly working on more complex and specialised areas. Delivering Value:
  4. 4. Their business philosophy, based on delivering value to our stakeholders, constantly inspires our people to innovate, excel and set new global benchmarks. Their multicultural workforce, comprising more than 14,600 employees of over 50 nationalities, gives them the strength to make quality healthcare accessible to people around the world. They remain committed to aggressively pursuing their mission of ‘Enriching lives globally, with quality and affordable pharmaceuticals’. Mission: Enriching lives globally, with quality and affordable pharmaceuticals Values: 1. Achieving customer satisfaction is fundamental to the business 2. Provide products and services of the highest quality 3. Practice dignity and equity in relationships and provide opportunities for the people to realise their full potential 4. Ensure profitable growth and enhance wealth of the shareholders 5. Foster mutually beneficial relations with all the business partners 6. Manage the operations with high concern for safety and environment 7. Be a responsible corporate citizen Top Products of Ranbaxy: Molecule Drug Class Atorvastatin & Combinations Hypolipidemics Donepezil Anti-Alzheimer’s Valacyclovir Anti-Virals Simvastatin Hypolipidemics Amoxicillin+Clavulanic Acid Anti-bacterials Ketorolac Analgesics Ciprofloxacin & Combinations Anti-bacterials Imipenem + Cilastatin Anti-bacterials
  5. 5. Loratadine& Combinations Anti-histaminics Fenofibrate& Combinations Hypolipidemics Amoxicillin & Combinations Anti-bacterials Cephalexin Anti-bacterials Clarithromycin Anti-bacterials Ambazone Oral Antiseptics Pantoprazole & Combinations Proton Pump Inhibitor THERAPIES: Anti – Infectives Ranabaxy has a significant presence in the Anti-infectives segment having leadership position in key markets in Penicillins, Cephalosporins, Macrolides, Flouroquniolones, Anti-fungals, Anti-virals, Anti-retrovirals (ARVs) and critical care. Their leading molecules in this segment are Valacyclovir, Amoxicillin + Clavulanic Acid, Ciprofloxacin, Imipenem + Cilasatin and Amoxicillin. Besides India, the other important markets where they have a strong presence in this segment are the US, South Africa, Russia, France, Germany, Romania, Brazil, Poland, Thailand and Malaysia. Penems form an important part of our portfolio. They sell Imipenem +
  6. 6. Cilastatin in more than 50 countries. On April 25, 2012, they launched India’s first New Chemical Entity (NCE), SynriamTM, for the treatment of uncomplicated falciparum malaria. It is a fixed dose combination of Arterolane 150 mg and Piperaquine 750 mg. Cardio –Vascular Cardiovascular (CVS) ailments are on the rise all over the world due to changing lifestyles. As a result, there is an increasing need for CVS drugs. Ranbaxy has been at the forefront of developing affordable, quality drugs for various CVS ailments like Hyperlipidemia, Hypertension and Diabetes. Strengthening the global leadership in statins, they launched their generic version of the world’s largest selling drug (Atorvastatin) in the US as a First-to-File (FTF) product. Today, Atorvastatin is marketed by us in more than 25 countries worldwide, including the US, India, Canada, Romania, South Africa, Australia and Malaysia. In markets like India, Romania, Russia, South Africa and Malaysia, Ranbaxy is among the leading companies
  7. 7. selling Simvastatin, Rosuvastatin, Aspirin, Losartan and Acarbose formulations. Pain and Muskuloskeletal Some of their best-selling molecules in the Pain and Musculoskeletal segment are Ketorolac, Diclofenac, Paracetamol and Ibuprofen combinations. They have launched specialised products like Cox 2 inhibitors for Osteoarthritis in several markets and are working on various specialised molecules to cater to this growing segment. Gastro-intestinal
  8. 8. Gastrointestinal is another significant therapeutic segment for Ranbaxy. Proton pump inhibitor (PPI) drugs for the treatment of ulcers are the leading drug class for them. In PPIs, like Pantoprazole, Rabeprazole, Lansoprazole and Omeprazole, they are leaders in several markets. Besides PPI, they have a strong presence in Ranitidine,H Pylori kits, Papain and digestive enzyme formulations. Respiratory There is a growing global population of patients with ailments relating to Chronic Obstructive Pulmonary Disease (COPD), which makes this therapy an important focus area for them. Ranbaxy has a significant presence in this segment, especially in the US, India, Eastern Europe, South Africa and Latin America. Some of our leading products in this segment are
  9. 9. Ambazone, Loratadine combinations, Triamcinolone, Montelukast and Fexofenadine. Central Nervous System (CNS) Ranbaxy has a wide portfolio of drugs for Central Nervous System (CNS) ailments like Schizophrenia, Epilepsy, Depression, Neuropathic Pain, Alzheimer’s Disease and Parkinson’s. Their leading molecules in CNS are Donepezil, Sertraline, Gabapentin, Pentazocine and Olanzapine. Anti–Retro Virals Ranbaxy offers a wide range of World Health Organisation prequalified (WHO PQ) Anti-retroviral (ARV) products that are supplied in
  10. 10. more than 100 countries in Africa, Latin America, CIS and Asia. Close to a million patients worldwide use the ARV products as part of the daily treatment regimen. Ranbaxy were among the first generic companies to offer ARVs to various National AIDS treatment programmes in Africa. Their ARV portfolio comprises Bio-equivalent Anti- retroviral products and Anti-infectives. The products are manufactured at our state-of-the-art facilities that have been approved by WHO PQ and/or stringent regulatory authorities. ARVs are being procured for large treatment programmes by major institutions such as Unicef, Global Fund – Voluntary Pooled Programme (VPP) (through PFSCM), UNITAID/CHAI (Clinton Health Access Initiative), Red Cross IDA, Missionpharma Crown Agents, Population Services International and United Nations Development Programme. Dermatology : Ranbaxy has a major focus in Dermatology with a presence across markets, including the US, India and Brazil. They also have a robust franchise in the Corticosteroids, Anti-infectives and Anti-acne segments. Their current portfolio in the US caters to both prescription and consumer driven Over-
  11. 11. the-Counter (OTC) markets, the major brands being Ultravate, Kenalog and Lac Hydrin. They have the global licensing rights to market Luliconazole (a novel Anti-fungal) in 16 markets, including India, Malaysia, Singapore and South Africa. Over The Counter (OTC) Products: Towards a Healthier World Ranbaxy Global Consumer Healthcare (RGCH) is a separate business division through which they develop and market Over-the-Counter (OTC) products in more than 20 countries across Asia, Africa, the Middle East and Europe. This division is one of our fastest growing and offers 15 products, including some top-selling brands that have leadership status in their respective segments. Some of our key OTC brands are Revital, Volini, Faringosept, Aspenter and Chericof. RGCH commenced its operations in 2002 with the launch of Pepfiz, Gesdyp and Garlic Pearls in the Indian market. The portfolio was strengthened with the addition of Revital. In 2005, Chericof was added to the offering and, in 2007, Volini, a topical analgesic brand, was introduced. Today, Revital, our flagship brand in the OTC segment, is India’s largest selling Vitamins & Minerals Supplement. It is also among the Top 5 OTC brands of India. Volini is among the fastest growing pain relievers available in India. It is also counted amongst the Top 10 brands in the Indian pharmaceutical market. Some of our other key OTC brands are Revital Woman, VoliniActiv and Revitalite. Providing Innovative Healthcare Solutions At RGCH, they strive relentlessly to enhance the well-being of consumers by providing innovative healthcare solutions. They follow the
  12. 12. model of staying in constant touch with the market through research and responding to its needs through appropriate products. The division has an aggressive sales and distribution strategy that involves penetrating Class II towns directly and smaller towns through the ‘hub and spoke’ model. They pursue a differentiated sales and distribution strategy of engaging FMCG/OTC distributors for our OTC products. The distribution infrastructure continues to grow, with about 1000+ distributors and sales representatives covering outlets that account for more than 90% of category volumes for all our major OTC brands. OTC Products Brand name Generic name Therapeutic segment REVITAL Ginseng, Vitamins and Minerals VMS-Vitamins, Minerals and Supplements REVITAL LIQUID Ginseng, Vitamins and Minerals VMS-Vitamins, Minerals and Supplements REVITAL WOMAN Ginseng, Vitamins and Minerals (Specially formulated for women) VMS-Vitamins, Minerals and Supplements REVITAL SENIOR Vitamins, Minerals, VMS-Vitamins, Minerals
  13. 13. Ginseng and Isoflavones (Specially formulated for 50 years+) and Supplements REVITALITE Soy Protein Supplement VMS-Vitamins, Minerals & Supplements VOLINI GEL Pain relief Gel ANALGESIC-Topical VOLINI SPRAY Pain relief Spray ANALGESIC-Topical VOLINI ACTIV GEL Ayurvedic Pain relief Gel ANALGESIC-Topical CHERICOF COUGH SYRUP Complete Cough Syrup for family CCA-Cough, Cold & Allergy PEPFIZ Effervescent digestive enzymes GI-Gastrointestinal GARLIC PEARLS Garlic oil for all round health GI-Gastrointestinal GESDYP Digestive Enzymes GI-Gastrointestinal OTC Products are Available Across Countries India Russia Romania Africa Vitamins & Dietary Supplements Revital Revital Woman Revital Senior Vitamins & Dietary Supplements Revital Garlic Pearls Fenules Heart Health Aspenter Aspacardin Vitamins & Dietary Supplements Revital Riconia
  14. 14. Revitalite Pain Relievers Volini Gel & Spray VoliniActiv Pain Relievers Brustan Vitamins & Dietary supplements Glubifer Pain Relievers Painamol Brustan Gastrointestinal Remedies Pepfiz Garlic Pearls Gesdyp Gastrointestinal Remedies Pepfiz Gastrointestinal Remedies Furazolidon Gastrointestinal Remedies Pepfiz Gestid Vomidon Cough & Cold Remedies Chericof Cough & Cold Remedies Coldact Flu Plus Faringosept Cough & Cold Remedies Faringosept Cough & Cold Remedies Rhineton Chericof
  15. 15. 2013 Award ASSOCHAM Innovation Excellence Platinum Award Ranbaxy wins the ASSOCHAM Innovation Excellence Platinum Award for SynriamTM, a new age cure for malaria Golden Peacock Award Ranbaxy wins the Golden Peacock Innovative Product/Service Award for SynriamTM, a new age cure for malaria 2012 Frost & Sullivan Pharmaceutical Company of the Year Ranbaxy wins the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category Best Pharma Company for the year 2011 – Dun & Bradstreet
  16. 16. Ranbaxy is awarded the Best Pharma Company of the Year 2011 by Dun & Bradstreet 2011 Padma Shri, the Fourth Highest Civilian Award in India, for Dr. NityaAnand, Chairman of Ranbaxy Science Foundation Dr. NityaAnand, Chairman of Ranbaxy Science Foundation, is honoured by the President of India with the Padma Shri, the Fourth Highest Civilian Award, in recognition of his notable performance in the field of drug research The Economic Times IMEA 2011 – Gold Award in the Pharmaceuticals Sector Ranbaxy wins the Economic Times IMEA 2011 – Gold Award in the Pharmaceuticals Sector. The award is conceptualised and instituted by Frost and Sullivan in collaboration with The Economic Times New Jersey Business and Industry Association Award for Excellence Ranbaxy is felicitated with the New Jersey Business and Industry Association Award for Excellence in the Business Expansion Category Brand of the Year 2011 Award for Revital and Volini
  17. 17. Ranbaxy bags ‘Brand of the Year 2011 Award for Revital and Volini’ at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce India’s most Admired Nutrition and Neutraceuticals for Revital Woman Ranbaxy wins Award for the Year 2011 for ‘India’s most Admired Nutrition and Neutraceuticals’ for Revital Woman at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce Pharma OTC Company of the Year 2011 Ranbaxy is recognised as ‘Pharma OTC Company of the Year 2011′ for its Global Consumer Healthcare Division at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo- American Chamber of Commerce CSR Organisation of the Year 2011 Ranbaxy wins the title of ‘CSR Organisation of the Year 2011′ at the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-American Chamber of Commerce 2010
  18. 18. Best Policy Holder Award Ranbaxy bags the Best Policy Holder Award in the category of Best Compliance Practices Reader’s Digest Trusted Brand Revital is recognised as the ‘Reader’s Digest Trusted Brand’ in the Health & Personal Care (Vitamin/ Health Supplements) category in 2010. Revital receives the exclusive gold award in the category Nigerian Awards for Roscillox and Gestid The Institute of Direct Marketing of Nigeria recognises Ranbaxy’s Roscillox suspension as the most effective and preferred antibiotic in its segment. Gestid bags the Excellence Award in the category of Antacid Brand of the Year from the Institute of Brand Management, Nigeria SammanPatra Ranbaxy’s plant in Dewas, Madhya Pradesh, India receives the ‘SammanPatra’ for being ranked 2nd in the category for contribution towards service tax Thompson Reuters Innovation Award
  19. 19. Ranbaxy is felicitated with the Thompson Reuters Innovation Award, in recognition of being India’s Most Innovative Pharma Corporate Enterprise for the year 2010 No. 1 in the Generics Category Ranbaxy is ranked No. 1 in the Generics category in improving access to needed medicines in a study in 2010 by Access to Medicine (ATM) foundation, a Netherlands- based non-profit organisation which is an initiative to improve access to medicines worldwide 2009 Outstanding Contribution to the Pharmaceutical Industry Ranbaxy is recognised for its ‘Outstanding Contribution to the Pharmaceutical Industry’ by Pharmexcil, India 2007 Most Respected Company of the Year Ranbaxy is ranked No. 1 in the pharma sector in the Most Respected Companies Survey by Business World, India’s leading business magazine Most Innovative Company of the Year Ranbaxy is recognised as one of the Most Innovative Companies in a survey by Business Today, a leading business magazine in India Largest Employer of the Year in the Pharmaceutical Industry
  20. 20. NJBIZ, the leading business publication in New Jersey, recognises Ranbaxy as one of the largest employers in the pharmaceutical industry in the state of New Jersey in the US Marketing Excellence Award for Volini Organisation of Pharmaceutical Producers of India (OPPI) selects Ranbaxy’s leading brand Volini for the Marketing Excellence Award 2007 in the new product category IPA Bilcare Award for Packaging Ranbaxy wins the IPA Bilcare Award for its ‘Twin pocket nested pouch’ developed by the R&D Packaging Team Pharma Excellence Award Ranbaxy is felicitated with the Pharma Excellence Award for ‘Leveraging Global Opportunity’ by the Express Pharma Group. It is lauded for creating a niche for itself in the most competitive global pharmaceutical industry 2006 Prestigious Private Label Supplier of the Year Award Ranbaxy’s US subsidiary, Ohm Labs receives the prestigious Private Label Supplier of the Year Award from AmerisourceBergen, one of the world’s largest pharmaceutical services companies serving the US, Canada and other select markets National Award for Excellence in Water Management Ranbaxy’s manufacturing plant in Toansa, Punjab, India receives the National Award for Excellence in Water Management 2005 for being an ‘Excellent Water
  21. 21. Efficient Unit’ Ranbaxy Russia – Company of the Year Award Ranbaxy Russia is bestowed with the ‘Profession is Life – Company of the Year Award’ in the category of ‘Manufacture and Promotion of Medical Goods and Services’ in 2006 Most Consistent Wealth Creator Ranbaxy is honoured in India as the nation’s ‘Most Consistent Wealth Creator’ by MotilalOswal Securities, for the period 1991-2006. The Annual Wealth Creation Study identifies the top 100 wealth creators amongst companies that have added at least Rs. 1 billion to their market capitalisation during the period 2000-06 Terapia Ranbaxy Awarded European Health 2006 Trophy Reader’s Digest awards Terapia Ranbaxy the European Health 2006 Trophy for Excellence in Communication 2005 US Subsidiary Receives Supplier Quality Award Ranbaxy’s US subsidiary receives the Supplier Quality Award from Cardinal Health, the second largest wholesaler in the US US Subsidiary Receives the Supplier Award from Walmart Ranbaxy’s US subsidiary receives the prestigious Supplier Award from Walmart, the largest chain store in the US, for outstanding performance in the first quarter of 2005 Amity Global Corporate Excellence Award Ranbaxy receives the Amity Global Corporate Excellence Award as a recognition of its best practices
  22. 22. Ranbaxy among India’s Best Managed Companies of the year Ranbaxy is featured in the elite group of India’s Best Managed Companies in a survey conducted by Business Today, the largest-circulated business fortnightly in India 2004 Pharma Pulse Award Ranbaxy receives ‘Pharma Pulse Award’ for being the best exporter of the year Yanhcheng Friendship Award Ranbaxy Guangzhou China Limited wins the Yanhcheng Friendship Award for its contribution to the local economy and the development of the society of Guangzhou, China National Award for excellence in Energy Management Ranbaxy’s manufacturing facility in Toansa, Punjab, India wins the National Award for Excellence in Energy Management Business of the Year Award
  23. 23. Ranbaxy and Ohm Labs bag the prestigious ‘Business of the Year Award’ from Brunswick Chamber of Commerce, US Indiastar Award Ranbaxy receives the prestigious Indiastar Award of the Year for Best Packaging Greentech Environment Excellence Award Ranbaxy’s plant in Toansa, Punjab, India bags the prestigious ‘Greentech Environment Excellence Silver Award’ in the pharma sector for the year 2003-04. The awards are given away by the Greentech Foundation, a Non GovernmentalOrganisation Frost & Sullivan Entrepreneurial Company of the Year Ranbaxy Brazil bags the prestigious Entrepreneurial Company of the Year Award from Frost & Sullivan Frost & Sullivan Award 2004 Ranbaxy US receives the Frost & Sullivan Award 2004 for Customer Value 2003 ET (The Economic Times) Award
  24. 24. Ranbaxy receives the ‘ET Award for Best Performing Company of the Year’ from The Economic Times, India’s largest business newspaper Best Exporter Award Ranbaxy bags the CONCOR (Container Corporation of India) Best Exporter Award for the year 2002-03 in the air exports category Top Products of Ranbaxy Molecule Drug Class Atorvastatin & Combinations Hypolipidemics Donepezil Anti-Alzheimer’s Valacyclovir Anti-Virals Simvastatin Hypolipidemics Amoxicillin+Clavulanic Acid Anti-bacterials Ketorolac Analgesics Ciprofloxacin & Combinations Anti-bacterials Imipenem + Cilastatin Anti-bacterials Loratadine& Combinations Anti-histaminics Fenofibrate& Combinations Hypolipidemics
  25. 25. Amoxicillin & Combinations Anti-bacterials Cephalexin Anti-bacterials Clarithromycin Anti-bacterials Ambazone Oral Antiseptics Pantoprazole & Combinations Proton Pump Inhibitor
  26. 26. Quality Leadership and Excellence by Design At Ranbaxy, our mission is to provide trusted medicines that help people lead healthier lives. The philosophy and intent are to create and maintain world-class business practices to ensure that our products are safe, effective and compliant with all internationally defined good practices. The passion for quality goes beyond business and statutory requirements. The only one focus – Patients. Their commitment to implementing a robust, global quality management system is based upon our desire to sustain a culture of operational excellence, meeting and exceeding the expectations of all stakeholders, including patients, customers and Government regulators. They are committed to fulfilling the spirit and intent of our Global Quality Philosophy at all locations where we conduct regulated research, development, manufacture, testing and/or distribution of pharmaceutical products. Their objective is sustained compliance with internationally defined good practices, collectively known as GxP. This includes Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Distribution Practice (GDP) and Good Pharmacovigilance Practice (GPVP). The commitment to GxP regulatory excellence supports our objective of providing safe and efficacious pharmaceutical products to our customers worldwide. Alignment with these standards provides the assurance that patient safety is protected and that the data provided to the regulators is of the highest accuracy, integrity and quality. Quality Mission Statement Ranbaxy partner’s with their stakeholders to assure high quality development, manufacture and distribution of reliable and safe medicines through: Qualified, responsible, and motivated employees Integrity of theirbehaviour and actions Effective and efficient GxP compliant quality systems Continuous quality improvement
  27. 27. Quality Management Principles Each of them is dedicated to contributing to the process of developing, manufacturing and distributing the company’s medicines in a manner that meets the safety, efficacy and compliance expectations of both customers and Government regulators. They adhere to the following principles when implementing our Global Quality Policy: Individual Responsibility – Quality is a part of our culture at Ranbaxy. Every employee is focused on quality Management Responsibility – Management allocation of appropriate resources for effective implementation of all required quality management systems designed to support and sustain a culture of continuing GxP compliance and operational excellence Accuracy and Ethics – Every employee shall generate and accurately document all required quality data in accordance with the highest ethical standards and Ranbaxy’s Code of Conduct principles Continuous Improvement – Quality performance indicators shall be measured and assessed with outcomes designed to drive continuous improvement in our quality systems and employee performance Quality Organisation Structure The global quality organisation is independently structured and resourced to fulfilorganisational responsibilities and global objectives as defined by our quality management system to ensure the achievement of established product quality standards. Quality System Management The quality system comprises both Quality System Controls and Quality Management Controls. Quality System Controls Quality System Controls assure that the development, manufacture, release and distribution of drug products take place through well-defined and well-documented quality systems and procedures. Key elements for Quality System Controls include: Facilities and Equipment System Materials System Production System Packaging and Labelling System Laboratory Controls Systems Quality Systems Quality Management Controls Quality Management Controls enable us to proactively analyse and manage the
  28. 28. performance of our global quality system. Our Quality Management Controls include QA/GxP processes for: Resource Management Employee Training Quality and Compliance Data Trending and Analysis Quality System Management Reviews GxP Document Management Our global document management hierarchy is outlined in the pyramid shown below: Inclusive and Motivating Principles Ranbaxy ensure’s that the processes of our business partners comply with national and international regulatory standards that are in alignment with those of their own. They have implemented a well-defined and thoroughly documented set of quality systems and procedures for our business partners. Quality means continuous improvement. Our Global Quality Standards are constantly benchmarked against best practices and so these are continually upgraded to keep pace with the changing dynamics of the global environment. They remain committed to the highest levels of professionalism and integrity and will ensure that all our facilities continue to meet the exemplary standards that are expected of a global pharmaceutical company
  29. 29. GDP % average annual GDP growth 1900 – 1950 1.0 1950 – 1980 3.5 1980 – 2002 6.0 2002 – 2006 8.0 2002-2012 UPTO 8.1
  30. 30. COMPARISON OF RANBAXY WITH OTHER COMPANIES CONCLUSION With a couple of sentences, I would like to address you that Ranbaxy Pharmaceutical Company
  31. 31. is growing on a larger scale. It has many benefits and profits which will be coming in the future years. Therefore, I would like to conclude that I thoroughly enjoyed working on this company as my assignment.